

UMA CO., LTD.

2-19-6 Yokosuka

Matsudo, Chiba, Japan



MEASURE UA

Reagent for determination of Uric Acid

Uricase/POD Method

↓ 2 - 8°C

IVD *In vitro* Diagnostics

QUALITY MANAGEMENT SYSTEM (BY TUV)

⊕ **DO NOT** freeze

⌚ 24 months/block from light

ISO 13485:2016

1. PURPOSE OF USE

Providing a quantitative *in vitro* assay for the Uric Acid (UA) concentration in serum or plasma.

2. GENERAL INSTRUCTION

- For *in vitro* diagnostics use only.
- Diagnosis should be made in a comprehensive manner, in accordance with other related test results and clinical symptoms by the doctor in attendance.
- For guaranteed results, usage of this product must comply with the instruction in this manual.
- If you use automatic analyzers, follow their instructions carefully.

SUMMARY

Uric acid is a product of purine metabolism. In humans and higher-order primates, there is a tendency to retain high levels of serum uric acid due to the loss of a key enzyme, uricase, which converts uric acid to water soluble allantoin. Elevated concentrations of uric acid in serum (hyperuricemia defined by serum uric acid concentration > 7 mg/dL in men and > 6 mg/dL in women), or elevated urinary uric acid concentrations (hyperuricosuria) can lead to gout and uric acid nephrolithiasis and increase the risk for hypertension, chronic kidney disease, and cardiovascular disease. Uric acid is a powerful scavenger of reactive oxygen species and is considered a key antioxidant in humans. However, high serum uric acid concentration is also associated with several diseases, including several linked to increased oxidative stress. Thus, the paradoxical role of uric acid as anti- and/or prooxidant has been the subject of an ongoing debate. Serum levels of uric acid are regulated by the balance between its production and excretion and is regulated by genetic and dietary factors. This chapter describes the biomedical importance of uric acid and health implications of hyperuricemia and gout.

3. MATERIALS REQUIRED BUT NOT INCLUDED

- Saline 0.9 % and high grade purified water
- Micropipet and other basic laboratory equipment.
- MEASURE Multi Calibrator and MEASURE Human Lyo L-1 and MEASURE Human Lyo L-2

4. REAGENT COMPOSITION & PREPARATION

- Reagent R-1: N-(2—hydroxy-3-sulfoethyl)-3,5-dimethylanilin sodium (HDAOS); Ascorbate oxidase (AOD); Peroxidase
Reagent R-1 is ready for use
- Reagent R-2: Uricase; Peroxidase (POD); 4-Aminoantipyrine (4-AA)
Reagent R-2 is ready for use
- Once open, Reagent stored on board the instrument is stable for 30 days with Hitachi 7180 Analyzers.
- Applicable to various automated analyzers.
- Calibrator MEASURE Multi Calibrator (separately sold): Put 5 mL of purified water to the vials of Calibrator (MEASURE Multi Calibrator), leave at room temperature for 45 minutes and sometimes gently invert the vial before use. After reconstituting, Calibrator can be used without dilution.
- Controls MEASURE Human Lyo L-1 and MEASURE Human Lyo L-2 (separately sold): Put 5 mL of purified water to the vials of controls (Lyo L-1 and Lyo L-2); leave at room temperature for 45 minutes and sometimes gently invert the vial before use. After reconstituting, controls can be used without dilution.

5. SAMPLE PREPARATION & STORAGE

- Serum: Wait until the sample is completely coagulated. Take the supernatant to use as specimens.
- Plasma: Treat sample by anticoagulant: Li-Heparin, K2-EDTA plasma; leave sample to stand for 3 hours or centrifuge at 2000 rpm for 2 minutes; take the plasma layer (supernatant) as sample.

Measure UA




- Stability in serum/plasma:

- 3 days at 20 - 25°C
- 8 days at 2 - 8°C
- 28 days at < -20°C

- See interferences section for details about possible sample interferences.

6. MEASUREMENT PRINCIPLE


In the first reaction, ascorbate oxidase eliminates ascorbate in the sample. In the second reaction, uricase and peroxidase generate blue-violet quinone pigment which enables the measurement of uric acid.



(λmax= 583 nm)

7. ASSAY PROCEDURE

This product is compatible with various types of clinical analyzer. An example of the assay procedure is indicated below.



————→ ΔAbs at 600/800nm —————→ Concentration UA

Perform the assay according to the instructions for operating the automated analyzer Hitachi models. Refer to the 13. INFORMATION FOR AUTOANALYZERS for the details of the assay method. Contact HUMA MEDICAL CO., LTD. for information about the parameters for other automated analyzers.

8. CALCULATION & UNIT CONVERSION

Calculation

- Calculate ΔAbs of specimen & standards vs blank

- Plot a calibration curve UA = f(ΔAbs)

- Calculate UA in specimen using the curve

(doing same procedure for Controls)

Unit conversion

$$\text{mg/dL} \times 10 = \text{mg/L}$$

$$\text{mg/dL} \times 59.5 = \mu\text{mol/L}$$

9. PERFORMANCE & CORRELATION TEST

a. Measuring range

- The assay is linear within an UA concentration range in serum/plasma of 5.95 - 5950 μmol/L.

- If the concentration of sample exceeds assay range, dilute the sample with saline and repeat the measurement.

b. Detection Limit

$$\text{Limit of Blank (LoB)} = 0.60 \mu\text{mol/L}$$

$$\text{Limit of Detection (LoD)} = 5.95 \mu\text{mol/L}$$

$$\text{Limit of Quantitation (LoQ)} = 5.95 \mu\text{mol/L}$$

The LoB, LoD and LoQ were determined in accordance with CLSI EP17-A2 requirements.

The LoB is the highest apparent analyte concentration expected to be found when replicates of a blank sample containing no analyte are tested. The LoB corresponds to the concentration below which analyte-free samples are found with a probability of 95%.

The LoD is determined based on the LoB and standard deviation of low concentration samples. The LoD corresponds to the lowest analyte concentration which can be detected (value above the LoB with a probability of 95%).

The LoQ is the lowest analyte concentration that can be reproducibly measured with a total error of 20%. It has been determined using low concentration samples.

c. Performance

- Sensitivity: Using purified water, absorbance change is 0.001 - 0.050, using solution of uric acid 595 μmol/L; absorbance change is 0.040 - 0.200

- Accuracy: When measuring a control sample is within ±10% of assigned value.

d. Precision (on Biolis 30i / SK300)

Representative performance data on the analyzers are given below.

Results obtained in individual laboratories may differ.

Precision was determined using controls followed the CLSI Approved Guideline EP5-A2 with repeatability, reproducibility and total precision (1 aliquot per run, 2 run per day, 20 days). The following results were obtained.

Criterion: CV of Repeatability (aka. Within-run precision) is less than 2% and Total Precision is less than 5%.

Repeatability	Mean µmol/L	SD µmol/L	CV %
Control Lyo L-1	293.7	3.16	1.08
Control Lyo L-2	665.0	4.25	0.64

Reproducibility	Mean µmol/L	SD µmol/L	CV %
Control Lyo L-1	293.7	7.28	2.48
Control Lyo L-2	665.0	12.13	1.82

Total precision	Mean µmol/L	SD µmol/L	CV %
Control Lyo L-1	293.7	7.60	2.59
Control Lyo L-2	665.0	12.50	1.88

e. Correlation Test

Serum (n = 50)

Regression equation: $y = 0.9995x - 0.0522$

Correlation coefficient: $r = 0.9979$

Plasma (n = 50)

Regression equation: $y = 1.0058x - 0.0454$

Correlation coefficient: $r = 0.9992$

(y: value obtained from using UMA's reagent)

Reference Materials for Calibration

ReCCS JCCRM 521

10. EXPECTED VALUES

Normal reference range

Serum/plasma

- Male 220 - 464 µmol/L

- Female 148 - 328 µmol/L

Reference range should be established at each facility and judgement should be based on measurement results in a comprehensive manner together with clinical symptoms and other measurement results.

11. INTERFERENCES

- Icterus: No significant interference of conjugated/free bilirubin concentration up to 40 mg/dL

- Hemolysis: No significant interference of hemoglobin concentration up to 500 mg/dL

- Lipemia (Intralipid): No significant interference triglycerides concentration up to 3000 FTU

- Ascorbic Acid: No significant interference of ascorbic acid concentration up to 50 mg/dL

- For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings. Please use another methods if the result is affected by any factors

12. HANDLING, USAGE & DISPOSAL**Handling**

1. Specimen can be potentially positive for infectious agents including hepatitis B virus and HIV. Wear glove and goggle when needed.

2. In case reagents got into skin, eye or mouth by mistake, wash it immediately with plenty of water and consult the doctor if needed.

3. If reagents are spilled, dilute with water and wipe it out. If specimen is spilled, spray 80% of alcohol over the specimen and wipe it out.

Usage

1. Store reagents under specified condition. Do not use after expiration date.

2. Do not use the container and auxiliaries included in this kit for other purposes.

3. Do not mix reagents of different lot for use.

4. Do not add to the reagent being used even if it is the same lot number.

Disposal

1. All specimens, as well as all instruments (e.g. test tubes) that come in contact with the specimens, must be treated by the following methods, or they must be treated according to the manual for infectious medical waste provided in each facility.

- Sterilize with an autoclave, subjecting them to high pressure saturated steam at 121 °C for more than 20 minutes. Do not process waste containing sodium hypochlorite solution with an autoclave.

* Immerse at least one hour in sodium hypochlorite solution (active chloride concentration of over 1000 ppm).

2. This reagent contains sodium azide. Sodium azide can react with lead pipe and/or steel pipe and can generate explosive metal azide. Make sure to use plenty of water at disposal. Concentration of sodium azide in R-2 is 0.05%.

13. INFORMATION FOR AUTOANALYZERS

❖ For Hitachi Model

Calculation Method		Two point
Temperature		37°C
	Specimen	3.0
Volume (µL)	R1	150
	R2	50
Wavelength (nm)	Main	600
	Sub	800
Measurement (cycle)	Point 1	10
	Point 2	16
	Point 3	34
Calibration type		Linear
Unit		mg/dL

14. OTHER INSTRUCTIONS AND CAUTION

- Results may differ depending on the sample/reagent ratio. Adjust parameters for different analyzer.

- Perform the QC procedure on the day of determination.

15. PACKING AND KIT CONFIGURATION

Code	Package	Test/Kit*	Test/Kit**
11U011A	1x60mL; 1x20mL	310	540
11U011A2	2x60mL; 2x20mL	620	1080
11U011A3	3x60mL; 3x20mL	930	1620
11U011A4	4x60mL; 4x20mL	1240	2160
11U001A	5x60mL; 5x20mL	1550	2700
11U011A6	6x60mL; 6x20mL	1860	3240
11U011	1x90mL; 1x30mL	470	810
11U011-2	2x90mL; 2x30mL	940	1620
11U001	3x90mL; 3x30mL	1410	2430
11U011-4	4x90mL; 4x30mL	1880	3240
11U011-5	5x90mL; 5x30mL	2350	4050

* For middle-scale automatic analyzers such as: SK300; BS series; BA200; BA400. Chemwell Series; Dirui Series; Biolyzer series, HumanStar 300, Erba Series; Bioelab Series, BX 3010; Pictus P500;...

** For large-scale automatic analyzers such as: CA800; CA400; Randox Imola; Randox Modena+; BM 6010; Biolis50i; SK500; AU Series; Pictus P700; C series; Ci series; HumanStar 600; Kenolab series ...

The above-mentioned test's number are calculated base on technical specifications of each analyzer. The real number of test per kit may higher than the calculation's number.

The above-mentioned test's number cover the loss of the dead volume of reagent bottles but not cover the loss of Calibrator and Control.

Please feel free to contact authorized distributor for further confirmation.

16. REFERENCES

1. Y. Xue, ... Navaid Iqbal, in Reference Module in Biomedical Sciences, 2014
2. CLSI/NCCLS Evaluation of Precision Performance of Clinical Chemistry Devices, EP05-A2, 2004
3. CLSI EP17 · Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, 2nd Edition, 2017
4. In house data, UMA Diagnostics

17. MANUFACTURER

UMA Co., Ltd.

2-19-6 Yokosuka, Matsudo City, Chiba

Prefecture 270-0031

TEL: 047-710-4871 (dial-in)

FAX: 047-710-4872